GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Estrella Immunopharma Inc (NAS:ESLA) » Definitions » Buyback Yield %

Estrella Immunopharma (Estrella Immunopharma) Buyback Yield % : 0.26 (As of Jun. 08, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Estrella Immunopharma Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Estrella Immunopharma's current buyback yield was 0.26%.


Estrella Immunopharma Buyback Yield % Historical Data

The historical data trend for Estrella Immunopharma's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Estrella Immunopharma Buyback Yield % Chart

Estrella Immunopharma Annual Data
Trend Jun21
Buyback Yield %
-

Estrella Immunopharma Quarterly Data
Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 0.74

Competitive Comparison of Estrella Immunopharma's Buyback Yield %

For the Biotechnology subindustry, Estrella Immunopharma's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Estrella Immunopharma's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Estrella Immunopharma's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Estrella Immunopharma's Buyback Yield % falls into.



Estrella Immunopharma Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Estrella Immunopharma's Buyback Yield for the fiscal year that ended in Jun. 2021 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0) / 0
=N/A%

Estrella Immunopharma's annualized Buyback Yield for the quarter that ended in Mar. 2024 is calculated as

Buyback Yield=Net Issuance of Stock(Annualized) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) * Annualized Factor / Market Cap
=- (-0.084 + 0) * 4 / 45.30464
=0.74%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the annualized quarterly data, the Repurchase of Stock and Issuance of Stock data used here is four times the quarterly (Mar. 2024) data.


Estrella Immunopharma Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Estrella Immunopharma's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Estrella Immunopharma (Estrella Immunopharma) Business Description

Traded in Other Exchanges
N/A
Address
5858 Horton Street, Suite 170, Emeryville, CA, USA, 94608
Estrella Immunopharma Inc is a preclinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer.

Estrella Immunopharma (Estrella Immunopharma) Headlines

No Headlines